SCHEMBL18110412

SCHEMBL18110412

Cn1cc(CCl)cn1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRA5 P31644 1/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KCNH2 Q12809 1/20 0.38
KDR P35968 1/20 0.37
EPHB4 P54760 1/20 0.37
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
MAPK1 P28482 1/20 0.35
GAA P10253 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM1A O60341 1/20 0.34
LMNA P02545 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HAT1 O14929 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356876 0.82
Hydrochloric Acid SCHEMBL9547234 0.80
Hydrochloric Acid SCHEMBL15262136 0.80 KCNH2 (0.44) GABRA1GABRA5KCNH2L3MBTL1GAA
SCHEMBL21589364 0.79 CYP3A4 (0.48) GABRA1GABRA5CYP3A4TDP1KDR
Hydrochloric Acid SCHEMBL20339542 0.79
Bromide SCHEMBL28418465 0.78 CYP3A4 (0.46) GABRA1GABRA5CYP3A4TDP1KDR
(Chloromethyl)Benzene SCHEMBL304085 0.72 CYP3A4 (0.60) CYP3A4TDP1RECQLGAAALDH1A1
SCHEMBL16877094 0.72 CALM1 (0.48) GABRA1GABRA5KCNH2KDREPHB4
SCHEMBL22871613 0.70 CYP3A4 (0.57) CYP3A4TDP1RECQLGAALMNA
Hydrochloric Acid SCHEMBL5143704 0.69 CYP3A4 (0.55) CYP3A4TDP1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077289-B2 Cyclosporins modified on the MeBmt sidechain by heterocyclic rings ALLERGAN, INC. (US) 2018-09-18 US disclosed
EP-3277704-A1 CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS ALLERGAN, INC. (US) 2018-02-07 EP disclosed
WO-2016160362-A1 CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS ALLERGAN, INC. (US) 2016-10-06 WO disclosed
US-20160289271-A1 Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings ALLERGAN, INC. 2016-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077289-B2 Cyclosporins modified on the MeBmt sidechain by heterocyclic rings CHP1, UACA, CRYAB GABRA1 1757/4885GABRA5 1663/4885CYP3A4 352/4885
US-20160289271-A1 Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings CHP1, UACA, CRYAB GABRA1 1757/4885GABRA5 1663/4885CYP3A4 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.